|
|
| home about us advertise with us downloads links privacy contact us site map copyright policy |
| ||
nmtb_breastcancernal pain or cramping, bloating, and altered bowel habits. While IBS may reduce quality of life or, rarely, be debilitating, it does not lead to permanent gastrointestinal seque-lae, such as intestinal bleeding, cancer or inflammatory bowel disease, nor does it short-en life expectancy. The abdominal discomfort in IBS may relate to increased sensitivity of the nerves in the colon, whereas changes in bowel habits are attributed to abnormalities in colonic muscular action and dis-ordered motility. www.centerwatch.com Irritable Bowel Syndrome page 2 Diagnostic criteria for IBS include at least three months of abdominal pain or discomfort relieved by defecation or associated with a change in bowel habits, plus two or more of the following symptoms occurring at least 25% of the time: change in stool frequency or form, altered stool passage, mucus in the stool and/or In a phase I/II trial, 50 patients of both genders reported a 75% positive response rate to PTI-901, as wellNVU 3047 Exe.Summary1 4.7recognize IBS as a common and bothersome medical disorder. Recent telephone surveys (the Gastrointestinal [GI] Sufferer Study, the Physician Study, and the IBS Medications Side Effects Study) explored patients' and physicians' thoughts, feelings, and perceptions of the physical, quality-of-life, and economic dimensions of IBS. These surveys also helped to uncover communication gaps that exist between patients and physicians. IBS in Women: The Unmet Needs integrates the results from these surveys with the published literature to provide a timely and compelling look at the significant impact of IBS symp-toms on womens' lives and the communication gaps that complicate the diagnosis and treat-ment of IBS. This Executive Summary highlights key points presented in detail in the full report. Sudden urges to have a bowel movement Rectal pain Straining Abdominal pain/discomfort Heartburn/acid reflux Bloating/distension Gas/gas pain Mean # of Days per well aware jan-feb05.inddintestine) that affects up to 20 percent of the U.S. population. IBS does not cause inflammation or destructive changes in bowel tissue nor does it increase the risk of colorectal cancer. There currently does not appear to be a link between IBS and inflammatory bowel diseases such as Crohn's disease or ulcerative colitis. IBS is not a disease, but rather a syndrome that may appear as a combination of signs and symptoms. During the course of the syndrome, signs and symptoms may unexpectedly get worse. The exact cause of IBS is unknown, but some researchers suggest it is caused by changes in the nervous system that controls sensation and muscle contractions in the bowel. An x-ray taken after administration of barium may help to improve visualization of the bowel. The most frequent clinical feature in IBS is a change in bowel habits. There is currently no cure for IBS, but many options are available for managing the signs and symptoms associated with the syndrome.ibs.inddIBS is characterized by a combination of persistent and recurrent abdominal pain that is associated with abnormal bowel habit (diarrhea, constipation or both). The pain often begins after eating and may be relieved after a bowel movement. Visceral hypersensitivity is increased symptoms of urgency and discomfort or pain when the bowel is stimulated or stretched. This discomfort or pain is similar to that produced in someone with a bowel obstruction where the intestinal wall is stretched (this is why many patients believe they have a bowel obstruction), or in someone who has a GI infection, or after overindulging food. This discomfort does not mean the bowel is damaged; only that it is more sensitive to these stimuli for persons with IBS. Brain-gut dysfunction is evident by the bowel overreacting to psychological stress, such as getting pain and diarrhea before an examination or constipation with traveling. Stress can affect bowel function in anyone, but the effectSpiller_abstractWe have defined Post infectious IBS (1) as acute onset Rome II criteria positive IBS developing after an infectious illness characterised by two or more of the following; fever, vomiting, acute diarrhoea, positive stool culture. Post infective IBS is of particular interest because it is "nature's experiment". Unlike most other IBS there is a clearly defined start date, and the condition is more homogenous, being mostly D-IBS. Epidemiology There have been at least 5 prospective studies of patients with culture positive infective gastroenteritis showing that 7 -31% progress to develop post infective IBS (PI-IBS) when assessed 3-6 months after infection (Table 1). When compared with uninfected controls two studies have shown an increased risk of developing IBS OR = 10.1, 95% CI = 3.32-30.69 (2;3). Risk factors for developing PI-IBS The strongest risk factor for developing PI-IBS is the duration of initial illness. When just a single organism is considered then bacterial56543 USC Excellence 4-05.v2Henderson replaced Stephen J. Ryan, who announced his resignation after 13 years as dean to return full-time to ophthalmology. Recruitment is proceeding at a strong pace. Henderson has made filling new research space with top scientists one of his key priorities. The quality of Keck School medical students is among the best in the history of the medical school, and students enrolled in graduate programs are reaching new heights. The original completion date for the project was January 2007, but shortages in staffing at the state agency charged with reviewing the project stalled the permit for Lee's gift will fund the center, which will be housed on the third or fourth floor of the USC/Norris Cancer Center. Lin's renowned clinical research has focused in part on the identification of the cause of irritable bowel syndrome and other poorly understood chronic disorders. Lin has proposed that the enigmatic-but-common condition known as irritable bowel syndrome, or IBS, isChronic Fatigue SyndromeBeginning in the early to mid−1980s interest in chronic fatigue syndrome was revived by reports in America and other countries of various outbreaks of long−term debilitating fatigue. Six million patient visits are made each year because of fatigue, although only a very small percentage of these can be attributed to actual chronic fatigue syndrome. Most studies indicate that girls are more apt to develop CFS than boys, although one study found the incidence of the syndrome to be equal. The link between psychological disorders and chronic fatigue syndrome is problematic because so many of the symptoms overlap. Because most of the features of CFS resemble those of a lingering viral illness, many researchers have focused on the possibility that a virus or some other infectious agent causes the syndrome in some cases. Well−designed studies of patients who met strict criteria for chronic fatigue syndrome and of patients with idiopathic chronic fatigue have not found an increaseduntitledResearch and Development Pipeline January 2005 Yamanouchi Pharmaceutical Co., Ltd. (1) Domestic: Research and Development Pipeline Stage Code No. / Generic name Therapeutic Target Classification Dosage Form In-house/Alliance Gelpart Harnal D (tamsulosin) Functional symptoms with Approved Alpha-1 receptor antagonist Oral In-house Orally disintegrating tablet benign prostatic hyperplasia <Approved in Sep. 2004> P-III YM617 (tamsulosin) Lower urinary tract syndrome Alpha-1 receptor antagonist Oral In-house YM086 (telmisartan) Diabetic nephropathy Angiotensin II receptor antagonist Oral Boehringer Ingelheim YM060 (ramosetron) Irritable bowel syndrome (IBS) 5HT3 antagonist Oral In-house YM026 (nateglinide) Type II diabetes (Concomitant treatment with Biganides) Rapid onset insulin secretion enhancer Oral Ajinomoto YM177 (celecoxib) Post surgical pain, post traumatic pain, tooth extract pain Cyclooxygenase-II inhibitor Oral Pfizer Irritable bowel syndrome (IBS)NEL251204R02_Russo_Anandamide (AEA) potentiates 5-HT1A and inhibits 5-HT2A receptors supporting therapeutic efficacy in acute and preventive migraine treatment. AEA is tonically active in the periaqueductal gray matter, a migraine generator. Fibromyalgia is now conceived as a central sensitization state with sec-ondary hyperalgesia. Cannabinoids have similarly demonstrated the ability to block spinal, peripheral and gastrointestinal mechanisms that promote pain in headache, fibromyalgia, IBS and related disorders. At the dawn of the 21st century, despite astounding progress in psychopharmacology, medicine remains challenged in its attempts to understand and success-fully treat a large number of recalcitrant syndromes, noteworthy among them, migraine, fibromyalgia, and irritable bowel syndrome (IBS). Migraine is a strongly genetic disorder, but similar symptoms are acquired under conditions of closed head injury, where the "post-traumatic syndrome" displays similar symptoms.The Medical Journal of AustraliaA 25-year-old man presented with macroscopic haematuria associated with a body mass index of 20 kg/m2 and a severe coagulopathy consistent with vitamin K deficiency. The diagnosis of a profound malabsorption syndrome secondary to coeliac disease was confirmed by small bowel histology and positive coeliac serology. (MJA 2005; 183: 321-323) A 25-year-old man presented to our hospital's emergency depart-ment with frank haematuria and bilateral loin pain. his doctor, based on a history of loose bowel motions over 2 years and a normal colonoscopy. A preliminary diagnosis of vitamin K deficiency, leading to a profound coagulopathy, secondary to a malabsorption syndrome from coeliac disease was made. Inflammatory bowel disease was a differential diagnosis, but inflammatory markers were only marginally elevated (Box 2). Delay in the diagnosis of coeliac disease is common (mean, 11 years).2 About 47% of patients will have been misdiag-nosed, and of those with classical symptoms97s-0163-let00773-vol23This is in response to your letter of July 14,2004 to the Food and Drug Administration (FDA). Your submission does not meet this requirement in that the notice does not contain the signature of a responsible individual who is certifying that the firm is in compliance with the requirements of the Act and the regulation. Therefore, your firm has not complied with the notification requirement in 2 1 U.S.C. 343(r)(6) and must submit notifications in accordance with the requirements in 21 CFR 101.93(a). The failure to submit a valid notice as required by the Act and the agency's regulation may subject your product to regulation under the drug provisions of the Act. Even if your submission complied with the requirements of the Act, information in your submission suggests that your products may violate one or more provisions of the Act. Your submission contained labels for three products that you market. The labels bear the following statements: The statements that you are makingSupplementary data-Defining chronic conditions for primaryHIV infection/AIDS Viral hepatitis Malignant neoplasm stomach Malignant neoplasm colon/rectum Malignant neoplasm pancreas Malignant neoplasm digestive other/NOS Congenital anomaly digestive system Congenital anomaly digestive system Duodenal ulcer Peptic ulcer other Diverticular disease Irritable bowel syndrome Chronic enteritis/ulcerative colitis Liver disease NOS Cholecystitis/cholelithiasis Disease digestive system, other ICPC-2 PLUS CODE 029 031 030 028 008 004 003 008 009 011 005 007 002 001 029 032 DESCRIPTION Chronic fatigue syndrome Myalgic encephalomyelitis Post viral fatigue syndrome Post viral syndrome Myelodysplastic syndrome Polycythaemia rubra vera Hepatitis B Hepatitis C Hepatitis D Atresia;biliary Cleft;palate/lip Disease;Hirschsprungs Harelip Megacolon;congenital Blind loop syndrome Insufficiency;pancreatic F H K F74 F83 F84 F92 F93 F94 H75 H82 H84 H86 K71 K72 K73 K74 K75 K76 K77 K78 K79 K80 Neoplasm of eye/adnexa Retinopathy Macular degenerationix of our contributing editors were among the attendees at the 2003 Digestive Disease Week (DDW) meetings. Here they report on noteworthy presentations in their respective areas of expertise, including new therapies and genetic markers for inflammatory bowel disease, advances in the use of endoscopic ultrasound and endoscopic retrograde cholangiopancreatography, gastroesophageal reflux disease, treatment of irritable bowel syndrome, and Helicobacter pylori. A second novel study, also presented at the plenary session, evaluated a different treatment modality - namely, food elimination diets - in IBS. Arguably, the results of this study could change current management of IBS. A second novel study, also presented at the plenary session, evaluated a different treatment modality--namely, food elimination diets--in IBS. Arguably, the results of this study could change current management of IBS. They entered 150 outpatients with all bowel habit subtypes of IBS and randomized them ngm_meet1On behalf of the Neurogastroenterology and Motility Section of the BSG, we are pleased to be able to welcome you to Robinson College. As well as being principal investigator in a number of physiological studies of new pharmacological agents for the treatment of functional bowel disorders, Dr Houghton has given numerous research presentations at national and international meetings. Dr Hunter has published many research papers gastroenterology, especially irritable bowel syndrome and inflammatory bowel disease. 5. Sanger GJ. 5-hydroxytryptamine and functional bowel disorders. 6. Bearcroft CP, Perrett D, Farthing MJG. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Houghton LA, Atkinson W, Whittaker P, Whorwell PJ, Rimmer M, Fricker J, Jacques L, Mills J. A role for 5-HT in the postprandial exacerbation of symptoms in female patients with diarrhoea predominant irritable bowel syndrome. Houghton LA, AtkinsonThe McDougall Newsletter November CoverConsider the strongest contact with the world around you is through your food, processed and absorbed by your intestine. Research released Monday, November 18, 2002, at the annual scientific meeting of the American Heart Association, showed that people on the Atkins low-carbohydrate diet lost more weight and had better cholesterol and triglyceride counts than people on a traditional Heart Association-approved low-fat diet. We invite you to contribute your thoughts and recipes to the McDougall Newsletter also. They fear going out of their home because of the sudden onset of stomach pains and an uncontrollable urge to move their bowels; followed by a torrent of diarrhea - sometimes accompanied by blood and mucus. Mild Chronic Colitis Mild chronic colitis is commonly known as irritable bowel syndrome (abbreviated IBS - also known as spastic colitis and spastic colon). The idea that the mind can cause bowel disease has been one of the fundamental teachings for medical studentsDevinThis information may be freely copied and distributed only if unaltered, with complete original content including: © Devin Starlanyl 2002. It is not a musculoskeletal dysfunction. It's a disorder of the informational substances such as neurotransmitters, hormones, peptides, and other biochemical messengers which regulate and run the systems of the body and mind. It causes hypersensitivity to all sorts of stimuli, so it can amplify pain. There are no trigger points (TrPs) in FMS, only tender points, which do not refer pain. Fibromyalgia often occurs with chronic myofascial (my-oh-fass-shall) pain (CMP), which is a neuromuscular chronic pain condition with TrPs that can cause muscle weakness and dysfunction, and incapacitating, intolerable pain. They can cause irritable bowel syndrome, dizziness and loss of balance, buckling ankles and knees, pelvic pain, painful intercourse in women, impotence in men, and many more symptoms. Carpal Tunnel Syndrome, Migraines, TMJD, PiriformisFS 22Prolapse is a gynaecological hernia. Laxness of the walls in the vagina creates bulges from the organs that they support. This type of prolapse is sometimes associated with a hernia of the bowel at the top of the vagina, called the fornix, and this type of prolapse is an enterocele. The remaining urine then irritates the bladder, leading to bladder spasms, which cause urgency and are sometimes severe enough to produce a leakage involuntarily. A lax and irritable bladder may also leak during intercourse, due to pressure exerted upon it. Those who suffer from rectal prolapse complain of a sensation of bulging in the vagina when they strain to open their bowels. Urgency to open the bowels results in an anticlimax with very little bowel motion when sitting on the toilet, as the reflexes tend to be lost due to this pouch effect. Constipation and irritable bowel syndrome may result from this. Having said that, women do report improvement in bowel and urinary symptoms to some18_18The previous Technology Evaluation Center (TEC) Assessment focused on wireless capsule endoscopy for obscure digestive tract bleeding suspected to be of small-bowel origin and concluded that this use met TEC criteria. This update to the TEC Assessment reviews the available evidence on the use of wireless capsule endoscopy in clinical indications where small-bowel pathol-ogy other than bleeding is known or suspected. These studies provide consistent evidence that wireless capsule endoscopy may demonstrate small-bowel lesions suggestive of Crohn's disease in a significant proportion of patients ranging from 43 to 71% when all other conventional tests have been negative. For initial diagnosis of suspected Crohn's disease when all conventional diagnostic tests including SBFT have failed to reveal bowel lesions suggestive of Crohn's disease, the evidence suggests that wireless capsule endoscopy may demonstrate small-bowel lesions suggestive of Crohn's disease in a significant1 | 2 | 3
| 4 | 5 | 6
| 7 | 8 | 9
| 10 | 11 | 12
| 14 | 15 | | ||
